187 related articles for article (PubMed ID: 29856035)
1. Methods to Quantify Cell Signaling and GPCR Receptor Ligand Bias: Characterization of Drugs that Target the Endocannabinoid Receptors in Huntington's Disease.
Bagher AM; Laprairie RB; Kelly MEM; Denovan-Wright EM
Methods Mol Biol; 2018; 1780():549-571. PubMed ID: 29856035
[TBL] [Abstract][Full Text] [Related]
2. Biased Type 1 Cannabinoid Receptor Signaling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.
Laprairie RB; Bagher AM; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Mar; 89(3):364-75. PubMed ID: 26700564
[TBL] [Abstract][Full Text] [Related]
3. Positive allosteric modulation of the type 1 cannabinoid receptor reduces the signs and symptoms of Huntington's disease in the R6/2 mouse model.
Laprairie RB; Bagher AM; Rourke JL; Zrein A; Cairns EA; Kelly MEM; Sinal CJ; Kulkarni PM; Thakur GA; Denovan-Wright EM
Neuropharmacology; 2019 Jun; 151():1-12. PubMed ID: 30940536
[TBL] [Abstract][Full Text] [Related]
4. Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.
Dowie MJ; Bradshaw HB; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2009 Sep; 163(1):456-65. PubMed ID: 19524019
[TBL] [Abstract][Full Text] [Related]
5. The cytokine and endocannabinoid systems are co-regulated by NF-κB p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.
Laprairie RB; Warford JR; Hutchings S; Robertson GS; Kelly ME; Denovan-Wright EM
J Neuroimmunol; 2014 Feb; 267(1-2):61-72. PubMed ID: 24360910
[TBL] [Abstract][Full Text] [Related]
6. Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.
Laprairie RB; Kelly ME; Denovan-Wright EM
Neuropharmacology; 2013 Sep; 72():47-57. PubMed ID: 23602984
[TBL] [Abstract][Full Text] [Related]
7. Characterization of structurally novel G protein biased CB
Ford BM; Franks LN; Tai S; Fantegrossi WE; Stahl EL; Berquist MD; Cabanlong CV; Wilson CD; Penthala NR; Crooks PA; Prather PL
Pharmacol Res; 2017 Nov; 125(Pt B):161-177. PubMed ID: 28838808
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.
Scotter EL; Goodfellow CE; Graham ES; Dragunow M; Glass M
Br J Pharmacol; 2010 Jun; 160(3):747-61. PubMed ID: 20590577
[TBL] [Abstract][Full Text] [Related]
9. The endocannabinoid system in Huntington's disease.
Pazos MR; Sagredo O; Fernández-Ruiz J
Curr Pharm Des; 2008; 14(23):2317-25. PubMed ID: 18781982
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological selection of cannabinoid receptor effectors: Signalling, allosteric modulation and bias.
Manning JJ; Green HM; Glass M; Finlay DB
Neuropharmacology; 2021 Aug; 193():108611. PubMed ID: 34000272
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoids and Neurodegenerative Disorders: Parkinson's Disease, Huntington's Chorea, Alzheimer's Disease, and Others.
Fernández-Ruiz J; Romero J; Ramos JA
Handb Exp Pharmacol; 2015; 231():233-59. PubMed ID: 26408163
[TBL] [Abstract][Full Text] [Related]
12. Antagonism of Dopamine Receptor 2 Long Affects Cannabinoid Receptor 1 Signaling in a Cell Culture Model of Striatal Medium Spiny Projection Neurons.
Bagher AM; Laprairie RB; Kelly ME; Denovan-Wright EM
Mol Pharmacol; 2016 Jun; 89(6):652-66. PubMed ID: 27053685
[TBL] [Abstract][Full Text] [Related]
13. Cannabinoid receptor ligand bias: implications in the central nervous system.
Laprairie RB; Bagher AM; Denovan-Wright EM
Curr Opin Pharmacol; 2017 Feb; 32():32-43. PubMed ID: 27835801
[TBL] [Abstract][Full Text] [Related]
14. Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.
Horne EA; Coy J; Swinney K; Fung S; Cherry AE; Marrs WR; Naydenov AV; Lin YH; Sun X; Keene CD; Grouzmann E; Muchowski P; Bates GP; Mackie K; Stella N
Eur J Neurosci; 2013 Feb; 37(3):429-40. PubMed ID: 23167744
[TBL] [Abstract][Full Text] [Related]
15. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
16. The cannabinoid receptor CB1 contributes to the development of ectopic lesions in a mouse model of endometriosis.
Sanchez AM; Quattrone F; Pannese M; Ulisse A; Candiani M; Diaz-Alonso J; Velasco G; Panina-Bordignon P
Hum Reprod; 2017 Jan; 32(1):175-184. PubMed ID: 27821707
[TBL] [Abstract][Full Text] [Related]
17. Prospects for Creation of Cardioprotective Drugs Based on Cannabinoid Receptor Agonists.
Maslov LN; Khaliulin I; Zhang Y; Krylatov AV; Naryzhnaya NV; Mechoulam R; De Petrocellis L; Downey JM
J Cardiovasc Pharmacol Ther; 2016 May; 21(3):262-72. PubMed ID: 26487546
[TBL] [Abstract][Full Text] [Related]
18. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington's disease transgenic mice.
Dowie MJ; Howard ML; Nicholson LF; Faull RL; Hannan AJ; Glass M
Neuroscience; 2010 Sep; 170(1):324-36. PubMed ID: 20600638
[TBL] [Abstract][Full Text] [Related]
19. Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB
Navarro G; Borroto-Escuela D; Angelats E; Etayo Í; Reyes-Resina I; Pulido-Salgado M; Rodríguez-Pérez AI; Canela EI; Saura J; Lanciego JL; Labandeira-García JL; Saura CA; Fuxe K; Franco R
Brain Behav Immun; 2018 Jan; 67():139-151. PubMed ID: 28843453
[TBL] [Abstract][Full Text] [Related]
20. Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
Kokona D; Thermos K
Exp Eye Res; 2015 Jul; 136():45-58. PubMed ID: 25989217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]